Abstract
Background Preeclampsia is a complex syndrome that accounts for considerable maternal and perinatal morbidity and mortality. Despite its prevalence, no effective disease-modifying therapies are available. Maternal serum placenta-derived proteins have been in longstanding use as markers of risk for aneuploidy and placental dysfunction, but whether they have a causal contribution to preeclampsia is unknown.
Objective We aimed to investigate the genetic regulation of serum placental proteins in early pregnancy and their potential causal links with preeclampsia and gestational hypertension.
Study design This study used a nested case-control design with nulliparous women enrolled in the nuMoM2b study from eight clinical sites across the United States between 2010 and 2013. The first- and second-trimester serum samples were collected, and nine proteins were measured, including vascular endothelial growth factor (VEGF), placental growth factor, endoglin, soluble fms-like tyrosine kinase-1 (sFlt-1), a disintegrin and metalloproteinase domain-containing protein 12 (ADAM-12), pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin, inhibin A, and alpha-fetoprotein. This study used genome-wide association studies to discern genetic influences on these protein levels, treating proteins as outcomes. Furthermore, Mendelian randomization was used to evaluate the causal effects of these proteins on preeclampsia and gestational hypertension, and their further causal relationship with long-term hypertension, treating proteins as exposures.
Results A total of 2,352 participants were analyzed. We discovered significant associations between the pregnancy zone protein locus and concentrations of ADAM-12 (rs6487735, P=3.03×10-22), as well as between the vascular endothelial growth factor A locus and concentrations of both VEGF (rs6921438, P=7.94×10-30) and sFlt-1 (rs4349809, P=2.89×10-12). Our Mendelian randomization analyses suggested a potential causal association between first-trimester ADAM-12 levels and gestational hypertension (odds ratio=0.78, P=8.6×10-4). We also found evidence for a potential causal effect of preeclampsia (odds ratio=1.75, P=8.3×10-3) and gestational hypertension (odds ratio=1.84, P=4.7×10-3) during the index pregnancy on the onset of hypertension 2-7 years later. The additional mediation analysis indicated that the impact of ADAM-12 on postpartum hypertension could be explained in part by its indirect effect through gestational hypertension (mediated effect=-0.15, P=0.03).
Conclusions Our study discovered significant genetic associations with placental proteins ADAM-12, VEGF, and sFlt-1, offering insights into their regulation during pregnancy. Mendelian randomization analyses demonstrated evidence of potential causal relationships between the serum levels of placental proteins, particularly ADAM-12, and gestational hypertension, potentially informing future prevention and treatment investigations.
Competing Interest Statement
M.C.H. reports consulting fees from CRISPR Therapeutics; advisory board service for Miga Health; and grant support from Genentech (all unrelated to the present work).
Funding Statement
Support for performing DNA extraction and GWAS from the Indiana University Grand Challenges Precision Diabetes project funding. Q.Y. was partially funded by R03OD034501 from the U.S. National Institutes of Health (NIH). D.M.H. was partially funded by R01HD101246 from the U.S. NIH. M.C.H. was supported by K08HL166687 from the U.S. NIH and American Heart Association (940166, 979465). Original funding for nuMoM2b sample and data collection are noted in the study methods papers (HAAS et al. 2015, 2016).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nulliparous women with singleton pregnancies were recruited from hospitals affiliated with eight clinical centers: Case Western University; Columbia University; Indiana University; University of Pittsburgh; Northwestern University; University of California at Irvine; University of Pennsylvania; and University of Utah. The Data Coordinating and Analysis Center is RTI International. Each site's local governing Institutional Review Board(s) approved the protocol and procedures.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
To better tailor the manuscript for a clinical audience, we have made significant editorial changes, particularly to the Introduction and Discussion sections. The results remain unchanged since the last version.
Data Availability
The individual-level phenotype and genotype data have been reported earlier and are available upon request.
